Invitrogen™ MIP-3 beta/CCL19 Human ELISA Kit

Description

The Human MIP-3 beta/CCL19 ELISA quantitates Hu MIP-3β in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu MIP-3β. Principle of the method The Human MIP-3β solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

CCL19, also known as MIP-3 beta (Macrophage Inflammatory Protein 3 beta), is a member of the CC- subfamily of chemokines. It is most closely related to CCL21, with which it shares 32% amino acid sequence homology. CCL19 and CCL21 are expressed mainly by stromal cells in the T cell-rich zones of lymph nodes. They are critical mediators of the homeostatic trafficking of naive T cells and activated dendritic cells into the secondary lymphoid organs. CCL19 and CCL21 also play a role in T cell priming and activation, as well as the recruitment of lymphocytes to inflamed tissue. Both proteins signal via the G protein-coupled receptor, CCR7, which is expressed on T cells and mature dendritic cells. Although CCL19 and CCL21 both exhibit the same affinity for CCR7, only the binding of CCL19 results in the desensitization and internalization of the receptor.